A phase II study of APD403 in the prevention of chemotherapy-induced nausea and vomiting reported positive results in patients receiving highly emetogenic chemotherapy—either high-dose cisplatin, or cyclophosphamide and an anthracycline for breast cancer.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
